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Extrapyramidal side effects of antipsychotics are
linked to their association kinetics at dopamine D2
receptors
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& Steven J. Charlton 1
Atypical antipsychotic drugs (APDs) have been hypothesized to show reduced extra-
pyramidal side effects (EPS) due to their rapid dissociation from the dopamine D2 receptor.
However, support for this hypothesis is limited to a relatively small number of observations
made across several decades and under different experimental conditions. Here we show that
association rates, but not dissociation rates, correlate with EPS. We measured the kinetic
binding properties of a series of typical and atypical APDs in a novel time-resolved ﬂuor-
escence resonance energy transfer assay, and correlated these properties with their EPS and
prolactin-elevating liabilities at therapeutic doses. EPS are robustly predicted by a rebinding
model that considers the microenvironment of postsynaptic D2 receptors and integrates
association and dissociation rates to calculate the net rate of reversal of receptor blockade.
Thus, optimizing binding kinetics at the D2 receptor may result in APDs with improved
therapeutic proﬁle.
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Imbalances in dopamine signaling are believed to play an integralpart in the symptoms of schizophrenia. The efﬁcacy of allcurrently marketed antipsychotic drugs (APDs) is thought to be
mediated by attenuation of dopamine transmission through their
actions as antagonists or low efﬁcacy partial agonists at the dopa-
mine D2 receptor (D2R)1, 2. However, the therapeutic window, i.e.,
the margin between the therapeutic dose and the dose that produces
adverse side effects, varies considerably across these drugs1–6.
Extrapyramidal motor symptoms (e.g., acute dystonia and
parkinsonian symptoms such as bradykinesia and tremor) and
excess prolactin release are major adverse side effects of APDs
mediated by blockade of D2R signaling in the nigrostriatal
dopamine system and the tuberoinfundibular pathway, respec-
tively1–6. Many “typical” or ﬁrst-generation antipsychotics
(FGAs) exhibit a relatively narrow therapeutic window with
respect to these “on-target” side effects. The term “atypical” was
ﬁrst applied to clozapine, an efﬁcacious APD with markedly
lower “on-target” side effects when compared to FGAs, but that
carries the risk for agranulocytosis, a potentially life-threatening
off-target toxicity. From the study of clozapine and FGAs
emerged second-generation antipsychotics (SGAs) designed to
exhibit wider therapeutic windows3. However, certain SGAs ﬁrst
introduced as atypical have in subsequent studies been shown to
have therapeutic indices more consistent with typical APDs with
the converse also true for FGA/typical APDs, such as melperone7.
What is apparent is that despite more than 50 years of
pharmacological research into APDs, on-target side effects
remain a signiﬁcant problem, often resulting in poor drug
compliance. Thus, understanding their cause is a critical step
toward the design of better therapeutics2, 3, 8.
Several different pharmacological theories have been proposed
to account for the atypicality of SGAs. One proposed mechanism
is antagonism of the 5-HT2A receptor, which is thought to
“balance” striatal dopamine signaling and thus reduce extra-
pyramidal side effects (EPS)9–11. However, the observation that
the SGA amisulpride, which is considerably more D2 selective
over 5-HT2A yet still exhibits reduced EPS, suggests that this
theory cannot account for all examples of atypicality12, 13.
Another enduring theory of atypicality is based on the
dissociation kinetics of APDs from the D2R. This concept
originated from the observation that some atypical APDs have
lower afﬁnity for the D2R than typical APDs14–16, which was later
demonstrated to be due to a faster dissociation rate17–19. This led
Seeman and Kapur to propose the “fast off hypothesis,” whereby
rapid dissociation from the D2R contributes to the reduced side
effect proﬁle of atypical APDs13. Key to this hypothesis is the rapid
and transient nature of synaptic dopamine signaling. Rapid dis-
sociation of an antagonist will allow a greater fraction of D2Rs to be
bound by the transiently high local concentrations of released
dopamine, therefore out-competing the antagonist in a surmoun-
table fashion. In contrast, an antagonist with a slow dissociation rate
is unlikely to dissociate from the D2R in the short time frame
between dopamine release and re-uptake, blocking the receptor
regardless of the local concentration of dopamine that is achieved,
i.e., making the antagonism effectively insurmountable20.
The link between dissociation rate and “atypicality” has been
questioned, however, based in part on the fact that the atypical
APD olanzapine has relatively high afﬁnity for the D2R and
should, in theory, dissociate as slowly from the D2R as the typical
APD haloperidol3. This inference is based on the widely held
assumption that APDs exhibit similar association rates (kon)
for the D2R and therefore that afﬁnity is essentially driven by
differences in dissociation rate. Although association rates have
widely been assumed to be diffusion limited, we recently
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Fig. 1 Determination of PPHT-red equilibrium and kinetic binding parameters. a Saturation analysis showing the binding of PPHT-red to the human
dopamine D2R. CHO–D2R cell membranes (2 μg per well) were incubated for 120min with gentle agitation with increasing concentrations of PPHT-red.
Data are presented in singlet form from a representative of 13 experiments. b Observed association of PPHT-red binding to the human dopamine D2R. Data
are presented in singlet form from a representative of 13 experiments. c Plot of PPHT-red concentration vs. kobs. Binding followed a simple law of mass
action model, kobs increasing in a linear manner with ﬂuorescent ligand concentration. Data are presented as mean± s.e.m. from a total of 13 experiments.
d PPHT-red dissociation following addition of haloperidol (10 μM). Dissociation data are presented in mean± s.e.m. from four experiments performed
in singlet. All binding reactions were performed in the presence of GppNHp (100 μM) with nonspeciﬁc-binding levels determined by inclusion of
haloperidol (10 μM)
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found that the association rates differ by several orders of
magnitude across a range of structurally diverse D2R agonists21,
demonstrating that the mechanisms that determine association
rate can vary greatly with ligand structure.
The majority of drug-receptor-binding models assume free
diffusion of analytes such that the dynamics of the system are
reaction-limited. In certain tissue microenvironments, however,
this assumption may not be valid, due, in part, to limitations on
free diffusion arising from physical barriers. For example,
the small aqueous compartment within a dopamine synapse
(estimated to be 0.09–0.4 μm3)22 is unlikely to mix well with the
bulk aqueous phase surrounding the synapse under the temporal
and spatial scales over which neurotransmission operates. This
may have important implications with regard to the blockade of
dopamine synaptic signals and the ability of APDs to rebind free
receptors. Rebinding in this case describes the process whereby a
reversibly bound ligand dissociates from a receptor into the local
aqueous environment but then rebinds the same or a nearby
receptor before it is able to diffuse from the synaptic cleft23,
effectively maintaining a higher concentration of the drug near the
receptor. Under these conditions, the degree to which an indivi-
dual drug rebinds is determined by receptor density, the associa-
tion rate constant, and anatomical and physicochemical factors
affecting the diffusion of the ligand away from the receptor24.
Currently available equilibrium and kinetic data on the binding
of APDs to the D2R were derived over the past several decades
using an assortment of different methods. The most common
method has been to use radiolabeled compounds18, 19, 25,
although not all APDs are available as radioligands. Alternatively,
competition association assays formulated with a single
radioligand/tracer can enable the kinetics of unlabeled ligands to
be calculated26, 27. We have recently developed such an assay
utilizing time-resolved ﬂuorescence resonance energy transfer
(TR-FRET) to measure the binding kinetics of unlabeled D2R
agonists21, 28. In the present study, we use this method to
determine the kinetics of an extensive series of APDs under
physiological temperature and sodium ion concentration, and in
doing so explore the kinetic basis for on-target side effects.
We ﬁnd that association rates, but not dissociation rates, correlate
with EPS. EPS were predicted by a rebinding model that
integrates association and dissociation rates within the
microenvironment of postsynaptic D2Rs to calculate the net rate
of reversal of receptor blockade. In contrast, prolactin elevation
was directly correlated with APD off-rate from D2R. Thus,
optimizing binding kinetics at the D2R may result in APDs with
improved therapeutic proﬁle.
Results
Characterization of PPHT-red binding. Speciﬁc binding of the
agonist PPHT-red to human D2L receptor (hD2LR) expressed
in CHO membranes was saturable and best described by the
interaction of the ﬂuorescent ligand with a single population of
Table 1 Kinetic binding parameters of unlabeled dopamine D2 antagonists for human D2L receptors and their historical
classiﬁcation as atypical or typical and those characterized as typical/atypical
koff (min−1) kon (M−1 min−1) t1/2 (min) pKd pKi
SGA/Atypical
Paliperidone 0.44± 0.04 1.80± 0.29 × 108 1.58 8.60± 0.07 8.54± 0.07
Remoxipride 1.90± 0.55 1.16± 0.37 × 107 0.36 6.79± 0.04 6.68± 0.07
Clozapine 1.67± 0.25 8.23± 1.42 × 107 0.41 7.69± 0.02 7.60± 0.02
Ziprasidone 1.07± 0.52 1.61± 0.50 × 109 0.65 9.19± 0.18 9.16± 0.19
Risperidone 0.43± 0.05 4.38± 0.52 × 108 1.61 9.05± 0.01 8.95± 0.05
Sertindole 0.59± 0.01 4.91± 0.82 × 108 1.17 8.92± 0.07 8.89± 0.03
Quetiapine 1.01± 0.33 6.57± 0.85 × 106 0.69 6.82± 0.02 6.75± 0.07
Olanzapine 1.12± 0.12 1.79± 0.44 × 108 0.62 8.17± 0.09 8.08± 0.11
Asenapine 0.93± 0.06 2.17± 0.65 × 109 0.75 9.29± 0.16 9.29± 0.12
Amisulpride 0.83± 0.05 3.44± 0.50 × 108 0.83 8.61± 0.06 8.49± 0.07
FGA/Typical
(+)Butaclamol 0.026± 0.004 6.82± 2.44 × 108 26.65 10.37± 0.12 10.32± 0.13
Flupenthixol 0.072± 0.010 3.50± 0.72 × 108 9.63 9.67± 0.07 9.68± 0.10
Haloperidol 0.65± 0.07 2.13± 0.52 × 109 1.07 9.49± 0.08 9.48± 0.08
Fluphenazine 0.040± 0.004 1.13± 0.01 × 109 17.33 10.46± 0.06 10.29± 0.04
Chlorpromazine 2.20± 0.44 3.76± 0.70 × 109 0.32 9.24± 0.04 9.01± 0.11
Perphenazine 0.23± 0.02 1.29± 0.17 × 109 3.01 9.73± 0.06 9.53± 0.04
Triﬂuoperazine 0.22± 0.01 1.10± 0.20 × 109 3.15 9.69± 0.10 9.48± 0.04
Spiperone 0.038± 0.006 2.55± 0.12 × 109 18.24 10.84± 0.07 10.54± 0.04
Nemonapride 0.018± 0.001 1.44± 0.04 × 109 38.50 10.91± 0.03 10.39± 0.04
Droperidol 0.38± 0.04 2.01± 0.38 × 109 1.82 9.71± 0.10 9.99± 0.10
Typical/atypical
(−)Sulpiride 2.23± 0.93 1.60± 0.67 × 108 0.31 7.87± 0.06 7.58± 0.10
Thioridazine 1.41± 0.25 2.37± 0.61 × 109 0.49 9.21± 0.03 8.93± 0.05
Molindone 1.69± 0.45 8.69± 2.6 × 107 0.41 7.69± 0.10 7.57± 0.12
Loxapine 2.14± 0.33 4.04± 1.04 × 108 0.32 8.25± 0.05 8.18± 0.05
Raclopride 0.53± 0.14 6.69± 2.04 × 108 1.31 9.08± 0.04 8.91± 0.08
Melperone 1.48± 0.18 1.99± 0.41 × 107 0.47 7.11± 0.04 7.05± 0.03
Zotepine 1.41± 0.34 9.15± 1.63 × 108 0.49 8.76± 0.17 8.69± 0.11
Peripheral acting
Domperidone 0.14± 0.02 9.73± 1.66 × 108 4.95 9.83± 0.07 9.81± 0.09
Data are mean± s.e.m. from four experiments performed in singlet. FGA/typical and SGA/atypical classiﬁcation is based on reference sources2, 3, 30. A number of APDs have been classiﬁed as both
typical and atypical APDs in separate studies. To recognize this, we have placed these drugs in a third group “typical/atypical” that includes sulpiride60–62, melperone7, 62, 63, loxapine58, 59, 64,
molindone65–67, zotapine7, 61, raclopride68, 69, and thioridazine62, 66, 70. Domperidone is not an APD and is used to block D2 receptors in the periphery
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binding sites (Fig. 1a). From these studies, the equilibrium
dissociation constant (Kd) of PPHT-red was determined to be
16.3± 0.9 nM. The expression level of the hD2LR recombinantly
expressed in CHO cells was assessed, using [3H]-spiperone
saturation binding and determined to be 1.13± 0.11 pmol mg−1
protein.
The binding kinetics of PPHT-red were characterized by
monitoring the observed association rates at six different ligand
concentrations (Fig. 1b). The observed rate of association was
related to PPHT-red concentration in a linear fashion (Fig. 1c).
Kinetic rate parameters for PPHT-red were calculated by globally
ﬁtting the association time courses, resulting in a kon of
2.3± 0.14 × 107M−1 min−1 and a koff of 0.33± 0.01 min−1. The
resulting Kd (koff/kon) of 15.4± 0.11 nM was comparable to that
obtained from the equilibrium studies. Ligand dissociation
estimated directly through addition of an excess of haloperidol
revealed a koff value of 0.52± 0.04 min−1, which was in good
agreement with the value estimated from the global association
time course described above (Fig. 1d).
The binding afﬁnity of the various ligands for the hD2LR
was measured at equilibrium at 37 °C in a buffer containing
5′-guanylyl imidodiphosphate (GppNHp) (0.1 mM) to ensure
that antagonist binding only occurred to the G protein-uncoupled
form of the receptor. Binding afﬁnities (Ki values) for the APDs
studied are summarized in Table 1, and representative competi-
tion curves are presented in Fig. 2a. In this table we have
separated APDs into those described in literature as typical APDs,
those described as atypical and, in a third group, those that have
been described as both typical and atypical.
Representative kinetic competition curves for selected D2R
ligands are shown in Fig. 2b–d. Progression curves for PPHT-red
alone and in the presence of competitor were globally ﬁtted to
Eq. 3 enabling the calculation of both kon (k3) and koff (k4) for
each of the ligands, as reported in Table 1.
There was a very wide range in dissociation rates for the
different ligands, with t½ values between 0.32 min for
chlorpromazine to 38.5 min for nemonapride. To validate the
rate constants, the kinetically derived dissociation constant (Kd)
values (koff/kon) were compared with the dissociation constant
(Ki) obtained from equilibrium competition binding experiments
(see Supplementary Fig. 1). There was a very good correlation
between these two values for all APDs tested (two-tailed
Pearson’s correlation r2= 0.98, P< 0.0001) indicating the
kinetic parameters were accurate. Previous radioligand-binding
studies have reported differences in dissociation rates of the order
of 100-fold between the typical APD chlorpromazine and the
atypical drugs, clozapine and quetiapine18, 19, 29; however, the
present study did not corroborate these ﬁndings. The most
plausible explanation for the differences observed between this
and the original studies is the use of different temperatures to
study the kinetics of these compounds coupled with the use of a
subsaturating concentration of dopamine (100 nM) as the cold
competing ligand, which may not be sufﬁcient to fully prevent
rebinding of the radioligand18, 29, 30.
Comparing kinetics and on-target side effects of APDs.
Historically, the link between APD D2R afﬁnity and dissociation
rate is based on the assumption that APDs exhibit approximately
the same kon for D2Rs19. However, we observed an increased
range in kon values between the atypical APDs compared to a
relatively small range in koff values. In contrast, for typical APDs
there was a much narrower variation in the value of kon and
differences in afﬁnity were driven instead by changes in koff.
Notably, however, the typical APD chlorpromazine exhibits koff
values similar to, or indeed faster than atypical APDs (Table 1).
We have correlated our kinetic binding data with clinical ﬁndings
taken from a recent meta-analysis of multiple-treatments studies
comparing side effect proﬁles across a diverse group of APDs31.
Both prolactin elevation and EPS are “on-target” adverse side effects
related to D2R blockade, whereas adverse effects, such as QT
interval and sedation, are generally considered “off-target” effects.
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Fig. 2 Equilibrium and competition association binding. a Competition between PPHT-red (12.5 nM) and increasing concentrations of representative
atypical and typical APDs clozapine, (−)sulpride, ziprasidone, haloperidol, (+)butaclamol, ﬂuphenthixol, and molindone at the human dopamine D2R. PPHT-
red competition association curves in the presence of b clozapine, c haloperidol, and d (+)butaclamol. All binding reactions were performed in the presence
of GppNHp (100 μM) with nonspeciﬁc-binding levels determined by inclusion of haloperidol (10 μM). Kinetic and equilibrium data were ﬁtted to the
equations described in “Methods” section to calculate Ki, Kd, and kon and koff values for the unlabeled ligands; these are summarized in Table 1. Data are
presented as singlet values from a representative of four. All data used in these plots are detailed in Table 1
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In contrast with the “rapid dissociation hypothesis”13, the
kinetic kon, but not koff, was positively correlated with the
incidence of EPS (Fig. 3a, b, Spearman’s rs= 0.68, P< 0.05 and
rs= −0.13, P= 0.68, respectively). On the other hand, prolactin
increases were correlated with the kinetic koff but not the kon (see
Fig. 3d, c, Spearman’s rs= −0.82, P< 0.05 and rs= 0.12, P= 0.78,
respectively). An obvious outlier is the atypical APD aripiprazole,
which displays an extremely slow koff21 but displays very little
propensity to cause prolactin release. It should be noted that the
mechanism of action of aripiprazole is different from other APDs
in that it is a low efﬁcacy partial agonist32, 33. As expected, QT
prolongation, an off-target side effect, correlated neither with kon
nor koff (Spearman’s rs= 0.09, P= 0.81 and rs= 0.30, P= 0.41,
respectively; see Supplementary Fig. 2a, b).
The majority of studies covered in the Leucht et al.31 meta-
analysis included as subjects chronically ill patients with a history
of APD exposure, which has been previously shown to change
D2R availability34. To address this issue, we used data from
available multiple treatment studies in ﬁrst-episode patients to test
correlations of kon and koff with EPS odds ratios (ORs) in patients
with minimal or no APD exposure. For the APDs tested in these
studies, we found that ORs of EPS were robustly predicted by kon
(Spearman’s rs= 0.90, P< 0.01) but not signiﬁcantly related to koff
(Spearman’s rs= −0.50, P= 0.22, see Fig. 3e, f).
Modeling rebinding at the D2R. Synapses are essentially minute
gaps across which a neurotransmitter diffuses and as such can be
considered receptor micro-compartments. While dopamine
terminals rarely form classical synapses, they do form appositions
with D2R-expression domains of target neurons that likely
impose diffusion constraints on drugs in these regions35, 36.
Models of receptor rebinding in situations with limited
diffusion allow the effect of kon and koff on the reversal of
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Fig. 3 Correlating clinical data on APD “on-target” effects with kinetically derived parameters. Correlation plots showing the relationship between a log kon
and EPS odds ratio and b log koff and EPS odds ratio and c log kon and prolactin increase and d log koff and prolactin increase. All kinetic data used in these
plots are detailed in Table 1 and clinical data are taken from Leucht et al.31. Kinetic data for aripiprazole were taken from Klein-Herenbrink et al.21.
Aripiprazole was not included in the correlation analysis as it is a dopamine D2R partial agonist. Correlation plot showing the relationship between e log kon
and EPS odds ratio and f log koff and EPS odds ratio, clinical data taken from ﬁrst-episode patient50–57. Kinetic data are presented as mean± s.e.m. from
four experiments and clinical data as standardized mean difference (SMD) for prolactin increase and odds ratio for EPS with associated credible intervals
where indicated. The relationship between two variables was assessed using a two-tailed Spearman’s rank correlation allowing the calculation of the
correlation coefﬁcient, rs. A P value of 0.05 was used as the cutoff for statistical signiﬁcance and relationships depicted as trend lines
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antagonist receptor occupancy to be considered collectively to
derive an overall reversal rate (kr) that provides a measure of the
local duration of antagonist effect24. The potential for rebinding
of APDs was modeled according to two different scenarios;
under conditions of limited diffusion (see Fig. 4a) such as
those encountered at the level of a synapse; or with free diffusion
(see Fig. 4b). In accordance with our current understanding of the
rebinding process, kon was the dominant factor in determining
the duration of target–receptor occupancy under conditions of
limited diffusion. In contrast, kon had little effect on-target
residency under conditions of free diffusion.
Consistent with our model, the correlation between kon and the
incidence of EPS observed in the Leucht study was mirrored by
the reversal rate kr, suggesting that kon is important in dictating
the reversal of D2R occupancy at the level of the synapse
(Spearman’s rs= −0.64, P< 0.05, see Fig. 4c). Interestingly, this
correlation was marginally stronger for ﬁrst-episode patients
receiving APDs (Spearman’s rs= −0.95, P< 0.01, see Fig. 4d).
In contrast, kr was not signiﬁcantly correlated with elevations
of prolactin (which is in agreement with the lack of correlation
with kon) (Spearman’s rs= −0.17, P= 0.68, see Fig. 4e).
Quetiapine
Quetiapine
Clozapine
Clozapine
100
Olanzapine
Risperidone
Haloperidol
Haloperidol
Receptor rebinding, i.e., limited diffusion No receptor rebinding, i.e., freely diffusing
100
50
0
6
2
1
0
4
2
EP
S 
od
ds
 ra
tio
EP
S 
od
ds
 ra
tio
0
1.5
1.0
0.5
0.0
–0.5
Pr
ol
ac
tin
 in
cr
ea
se
 S
M
D
–3 –2 –1 0
–3 –2 –1 0
–3 –2 –1 0
rs = –0.64, P = 0.03 rs = –0.96, P = 0.0011
rs = –0.22, P = 0.52
0 60 120
Time (min)
Rebinding log kr (min–1) Rebinding log kr (min–1)
Rebinding log kr (min–1)
Time (min)
180 1050 60 120 180
%
 re
ce
pt
or
s 
bo
un
d
50
0
%
 re
ce
pt
or
s 
bo
un
d
ZotepineChlorpromazine
Chlorpromazine
Quetiapine
Clozapine
Haloperidol
Chlorpromazine
Asenapine Ziprasidone
Sertindole
Paliperidone
Amisulpride
Quetiapine
Clozapine
Olanzapine
Risperidone
Haloperidol
Chlorpromazine
Asenapine
Ziprasidone
Paliperidone
Amisulpride
QuetiapineOlanzapine
Risperidone
Haloperidol
Chlorpromazine
Ziprasidone
Sertindole
a b
c d
e
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Discussion
The novel TR-FRET kinetic assay described herein has a
signiﬁcantly improved throughput relative to more traditional
radioligand binding assays. This has enabled us to accurately
quantify, for the ﬁrst time, the kinetic rate constants of a large
number of unlabeled dopamine D2 antagonists under identical
test conditions, allowing us to better investigate a role for kinetics
in the side effect liability of clinically used APDs.
It has been widely assumed that association rates for APDs are
diffusion limited and therefore comparable, meaning that the
dissociation rate determines their afﬁnity37, 38. Our TR-FRET
data, however, revealed a surprisingly wide range of both
association and dissociation rates across the ligands studied,
demonstrating the importance of directly measuring rate
constants. For example, the suggestion that the high-afﬁnity
atypical APDs olanzapine and risperidone should have koff values
similar to haloperidol3 is not supported by our kinetic data.
We correlated our new kinetic binding data with clinical
data that quantiﬁed the level of extrapyramidal side effects
and hyperprolactinemia associated with a diverse group of
clinical APDs. The clinical data were taken from a recent and
relatively comprehensive multiple-treatment meta-analyses of
antipsychotic drug efﬁcacies31 and a summary of the primary
literature on studies of drug-free patients. While meta-analytic
methods assure the best control for the quality of the data across
studies, it is important to note that because their focus was
efﬁcacy, EPS were often not a well-controlled outcome of the
studies included in the meta-analysis. Indeed, the present models,
like preceding hypotheses on EPS, are limited by the relative
paucity of studies comparing antipsychotic drugs in which EPS
are a primary outcome controlled for the minimum dose required
to treat the psychosis or for adjunct treatments. To address this,
we performed an additional exploratory analysis of studies in ﬁrst
episode or early psychosis, drug-free patients.
Consistent with the fast-dissociation hypothesis of APD
atypicality, we found that hyperprolactinemia was correlated with
the dissociation rate (koff), with ligands that were the slowest
to dissociate from the D2R displaying the greatest liability for
prolactin elevation in patients. Surprisingly, however, we found it
was kon and not koff that was correlated with the incidence of EPS.
Thus, drugs that bind more rapidly have greater liability of EPS,
challenging the hypothesis that dissociation rate is the sole
determinant of a compound’s liability to produce this side
effect13. To illustrate, the typical APD chlorpromazine has a koff
value similar to that of clozapine, but has much greater EPS
liability. The increased propensity for EPS of chlorpromazine
relates instead to its rapid association rate (kon). A recent study by
Sahlholm and colleagues is consistent with this interpretation.
These authors used D2R-evoked potassium channel activation
to estimate receptor kinetics39, 40. Interestingly, the off rates
determined by this indirect measurement, which were broadly
consistent with the values obtained in the current study, did not
distinguish between the typical and atypical APDs.
To further explore this ﬁnding, we employed a more
holistic model of receptor binding that integrates both the
association and dissociation rates in a system mimicking
the environment of the synapse. This model assumes that
diffusion of the drug out of the synapse is reduced by the physical
barriers created by the pre- and post-synaptic membranes,
effectively creating a compartment separate from the bulk
aqueous phase. The consequence of this is that freshly dissociated
ligands tend to remain in close proximity with membrane
surfaces for longer, increasing the probability of a second binding
event to the same or nearby receptor24. By using our measured
association and dissociation rates in this model, we have
estimated the overall relative rate of reversal of receptor blockade,
termed kr24.
As illustrated in Fig. 4, compounds with similar afﬁnity and/or
koff do not share the same potential to rebind receptors, a process
which in the face of limited diffusion and subsaturating dopamine
concentrations is governed largely by kon. Remarkably when we
calculated the receptor reversal rate kr for each APD using the
measured kinetic parameters, we found that this parameter was
signiﬁcantly correlated with the incidence of EPS, (Spearman’s
rs= −0.64, P< 0.05 see Fig. 4c). The active standardized mean
difference (SMD) produced a similar correlation with kon and kr,
strongly suggesting that the process of rebinding and associated
EPS liability may be a limiting factor for treatment effectiveness
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(see Supplementary Figs. 2c and 3a), ultimately leading to dis-
continuation of therapy (see Supplementary Figs. 2d and 3b).
Intriguingly, the correlation of kr with EPS was stronger for the
ﬁrst-episode patients (Spearman’s rs= −0.95, P< 0.01 see Fig. 4c),
which may reﬂect the fact that in this case EPS liability is
taken from well-controlled study outcomes in patients receiving
minimal adjunctive treatments.
We believe that there is no real improvement in correlation
with kr over kon because for the particular properties of our model
synapse, kon is the governing rate parameter for reversal of
binding. In other systems, this might not be the case. For
example, changes in the dimensions or receptor density of the
compartment might reduce the impact of rebinding, meaning kr
would be largely driven by koff. In these situations, it would be
expected that kr would be better correlated to EPS than kon.
Thus, kr represents a useful parameter with which to predict
the receptor occupancy of a drug with known kinetic binding
parameters under different degrees of limited diffusion.
Intriguingly, radioligand binding studies have demonstrated
that subsaturating concentrations of dopamine less readily dis-
place more rapidly associating radioligands, such as chlorpro-
mazine, compared to more slowly associating radioligands, such
as clozapine, despite their off rates being almost identical18. These
observations taken together with our model indicate that
rebinding maintains APD at a higher concentration in the
synaptic (or appositional) compartment, resulting in a more
effective competition for released dopamine. This, combined with
the close correlation between rebinding rates and EPS, leads us to
speculate that there is a minimum level of stimulation of post-
synaptic D2Rs that must be maintained in order to avoid EPS.
The ability of dopamine transmission to remain above this
threshold in the presence of an APD is determined in large part
by the APD’s rebinding rate. It is important, however, to
acknowledge that the data presented in this study do not rule out
alternative mechanisms that may contribute to the overall side
effect proﬁle of APDs, e.g., agonism at 5-HT1A41.
Interestingly, and in contrast to EPS, prolactin elevation was
not correlated with kr, reﬂecting the lack of correlation with kon.
This may reﬂect that dopamine and APDs diffuse into the
pituitary through the hypothalamic–pituitary portal system as
opposed to a synaptic apposition42–44. Since ligands diffuse
more freely around D2Rs on pituitary lactotrophs, their behavior
conforms to the laws of mass action and rebinding may be
negligible. As a consequence, the rate of reversal of APD-receptor
occupancy, and thus excess prolactin release, will depend
solely on the dissociation rate constant of APDs through the
phenomenon of insurmountable antagonism.
To summarize, we propose to expand the kinetic hypothesis
for APD side effects by considering not only the dissociation
rate (and therefore propensity to display insurmountable
antagonism), but also their association rate and potential
for receptor rebinding, leading to increased competition
with dopamine at the synapse (see Fig. 5a). Based on this
scheme, we propose the following three broad classes of
compounds to explain how these different kinetic characteristics
may inﬂuence on-target side effects in different tissues:
1. Fast on, slow off compounds, e.g., haloperidol. The fast on
rate results in a high receptor rebinding potential at D2Rs
apposed to dopamine release sites in the striatum and
therefore high EPS. In contrast, in the pituitary, the slow
dissociation rate results in insurmountable antagonism at
D2Rs leading to increased prolactin release.
2. Fast on, fast off compounds, e.g., chlorpromazine. Again, the
fast on rate leads to high rebinding potential in the striatum
and high EPS, but fast off rates result in surmountable
antagonism and thus reduced propensity for
hyperprolactinaemia.
3. Slow on, fast off compounds, e.g., clozapine. Slow on rates
result in lower rebinding potential in the striatum and low
EPS, and fast off rates lead to surmountable antagonism and
reduced hyperprolactinemia.
This classiﬁcation, summarized in Fig. 5b, suggests that slow
on/fast off kinetics is the optimal kinetic proﬁle for APDs
targeting D2Rs. Notably, the APD with the slowest association
rate is quetiapine, with a kon more than an order of magnitude
slower than clozapine. Curiously, this compound has been
found to be less efﬁcacious than risperidone and olanzapine in
treatment of chronic schizophrenia45. Quetiapine’s removal
from the comparisons between kon and active SMD resulted in a
much-improved correlation (Spearman’s rs= −0.85, P< 0.001;
see Supplementary Fig. 2c), suggesting it may not produce
sufﬁcient rebinding for a robust clinical effect. This problem is
likely to be further exacerbated by its short plasma half-life, which
will further reduce its receptor coverage over the dosing period46.
Moreover, our model and the relative positions of compounds
in Fig. 5a appear to help rationalize why certain compounds
originally introduced as SGA/atypical APDs have typical proﬁles,
e. g., zotapine, and conversely why drugs originally classiﬁed as
FGA/typical APDs, such as melperone, are capable of displaying
atypical behavior. The reality is that the side effects of APDs
comprise multiple, pharmacologically separable effects, hence
a more rational approach to classiﬁcation is to consider a
continuum based on the speciﬁc pharmacology of a given side
effect rather than the current dichotomous system. This has lead
us to speculate that there is likely to be a kinetic “sweet spot”
where rebinding is sufﬁcient for efﬁcacy but not enough to cause
EPS. Through optimization of these kinetic parameters, it may be
possible to develop a new generation of safer drugs for a disease
that still has high unmet medical need.
Methods
Materials. Tag-lite labeling medium (LABMED), SNAP-Lumi4-Tb, and the PPHT
((±)-2-(n-phenethyl-n-propyl)amino-5-hydroxytetralin hydrochloride;1-Naphtha-
lenol,5,6,7,8-tetrahydro-6-[(2-phenylethyl)propylamino]) derivative labeled with a
red ﬂuorescent probe (PPHT-red) was obtained from Cisbio Bioassays (Bagnols-
sur-Cèze, France). Ninety-six-well polypropylene plates (Corning) were purchased
from Fisher Scientiﬁc UK (Loughborough, UK) and 384-well optiplate plates were
purchased from PerkinElmer (Beaconsﬁeld, UK). GppNHp, risperidone, chlor-
promazine hydrochloride, quetiapine hemifumarate, ziprasidone hydrochloride
monohydrate, zotepine, sertindole, thioridazine hydrochloride, ﬂuphenazine
dihydrochloride, molindone hydrochloride, loxapine succinate, perphenazine, tri-
ﬂuoperazine dihydrochloride, spiperone, (−)-sulpiride, droperidol, and (+)-buta-
clamol used in competition assays were obtained from Sigma-Aldrich (Poole, UK).
Olanzapine, nemonapride, remoxipride hydrochloride, ﬂupenthixol dihy-
drochloride, paliperidone, amisulpride, melperone hydrochloride, clozapine,
raclopride, domperidone, asenapine maleate and haloperidol hydrochloride used
for competition assays were obtained from Tocris Bioscience (Avonmouth, Bristol).
Cell culture. The host Chinese hamster ovary (CHO) K1 cell line was provided by
Prof. J. Baker, University of Nottingham (ATCC #CCL-61). This was transfected
with the cDNA encoding a SNAP-tagged human dopamine D2L receptor (Genbank
ref.: NM_000795), and a stable dilution-cloned cell line (CHO–D2L) was established
by zeocin resistance encoded by the plasmid vector (pcDNA3.1zeo+, Invitrogen,
Paisley UK). Cells were maintained in Dulbecco’s modiﬁed Eagle’s medium: Ham
F12 (DMEM:F12) containing 2mM glutamine (Sigma-Aldrich, Poole, UK) and
supplemented with 10% fetal calf serum (Life Technologies, Paisley UK).
Terbium labeling of SNAP-tagged D2L cells. Cell culture medium was removed
from the t175 cm2 ﬂasks containing conﬂuent adherent CHO–D2L cells. Twelve
milliliter of Tag-lite labeling medium containing 100 nM of SNAP-Lumi4-Tb was
added to the ﬂask and incubated for 1 h at 37 °C under 5% CO2. Cells were washed
2× in PBS (GIBCO Carlsbad, CA) to remove the excess of SNAP-Lumi4-Tb then
detached using 5 ml of GIBCO enzyme-free Hank’s-based cell dissociation buffer
(GIBCO, Carlsbad, CA) and collected in a vial containing 5 ml of DMEM:F12
containing 2 mM glutamine (Sigma-Aldrich) and supplemented with 10% fetal calf
serum. Cells were pelleted by centrifugation (5 min at 1500 rpm) and the pellets
were frozen to −80 °C. To prepare membranes, homogenization steps were
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conducted at 4 °C (to avoid receptor degradation). Speciﬁcally 20 ml per t175-cm2
ﬂask of wash buffer (10 mM HEPES and 10 mM EDTA, pH 7.4) was added to
the pellet. This was homogenized using an electrical homogenizer Ultra-Turrax
(Ika-Werk GmbH & Co. KG, Staufen, Germany) (position 6, 4 × 5-s bursts)
and subsequently centrifuged at 48,000×g at 4 °C (Beckman Avanti J-251 Ultra-
centrifuge; Beckman Coulter, Fullerton, CA) for 30 min. The supernatant
was discarded, and the pellet was re-homogenized and centrifuged as described
above in wash buffer. The ﬁnal pellet was suspended in ice-cold 10 mM HEPES and
0.1 mM EDTA, pH 7.4, at a concentration of 5–10 mgml−1. Protein concentration
was determined using the bicinchoninic acid assay kit (Sigma-Aldrich), using BSA
as a standard and aliquots maintained at −80 °C until required. Prior to their use,
the frozen membranes were thawed and the membranes suspended in the assay
buffer at a membranes concentration of 0.2 mg ml−1.
[3H]-Spiperone saturation binding assays. Increasing concentrations of [3H]-
spiperone (0.020−1.2 nM) were incubated with human D2L CHO cell membranes
(10 μg per well) at 37 °C in assay binding buffer (20 mM HEPES 138 mM NaCl.
6 mM MgCl2, 1 mM EGTA, and 1 mM EDTA pH 7.4) containing 100 μM
GppNHp and 0.1% ascorbic acid in a 1 ml reaction volume. Non-speciﬁc binding
was determined in the presence of 3 μM (+)-butaclamol. After a 2 h incubation
period, bound and free [3H]-spiperone were separated by fast-ﬂow ﬁltration
through GF/B ﬁlters using a Filter Mate Harvester (PerkinElmer) followed by
2 ml wash with ice-cold PBS (Lonza). After drying, ﬁlter bound radioactivity
was measured following addition of 40 μl of Microscint 20 (PerkinElmer)
using a Topcount microplate scintillation counter (PerkinElmer). Aliquots of
[3H]-spiperone were also quantiﬁed accurately to determine how much
radioactivity was added to each well using liquid scintillation spectrometry
on a Tri-Carb liquid scintillation counter (PerkinElmer).
Fluorescent ligand-binding assays. All ﬂuorescent binding experiments using
PPHT-red were conducted in white 384-well Optiplate plates, in assay binding
buffer, 20 mM HEPES, 138 mM NaCl, 6 mM MgCl2, 1 mM EGTA, and 1 mM
EDTA and 0.02% pluronic acid pH 7.4, 100 μM GppNHp, and 0.1% ascorbic acid.
GppNHp was included to remove the G protein-coupled population of receptors
that can result in two distinct populations of binding sites in membrane
preparations, since the Motulsky–Mahan model26 is only appropriate for ligands
competing at a single site. In all cases, nonspeciﬁc binding was determined in the
presence of 10 μM haloperidol.
Determination of PPHT-red binding kinetics. To accurately determine
association rate (kon) and dissociation rate (koff) values, the observed rate of
association (kob) was calculated using at least four different concentrations of
PPHT-red. The appropriate concentration of PPHT-red was incubated with
human D2L CHO cell membranes (2 μg per well) in assay binding buffer (ﬁnal
assay volume, 40 μl). The degree of PPHT-red bound to the receptor was assessed
at multiple time points by HTRF detection to allow construction of association
kinetic curves. The resulting data were globally ﬁtted to the association kinetic
model (Eq. 2) to derive a single best-ﬁt estimate for kon and koff as described under
data analysis.
Competition binding kinetics. To determine the association and dissociation rates
of D2R ligands, we used a competition kinetic binding assay we recently described
to proﬁle the kinetics of a series of D2R agonists21. This approach involves the
simultaneous addition of both ﬂuorescent ligand and competitor to the receptor
preparation, so that at t= 0 all receptors are unoccupied. 12.5 nM PPHT-red
(a concentration which avoids ligand depletion in this assay volume, see
Carter et al.,47 was added simultaneously with the unlabeled compound (at t= 0) to
CHO cell membranes containing the human D2LR (2 μg per well) in 40 μl of assay
buffer. The degree of PPHT-red bound to the receptor was assessed at multiple
time points by HTRF detection.
Nonspeciﬁc binding was determined as the amount of HTRF signal detected in
the presence of haloperidol (10 μM) and was subtracted from each time point,
meaning that t= 0 was always equal to zero. Each time point was conducted on
the same 384-well plate incubated at 37 °C with orbital mixing (1 s of 100 RPM per
cycle).
Multiple concentrations of unlabeled competitor were tested for determination
of rate parameters. Data were globally ﬁtted using Eq. (3) to simultaneously
calculate kon and koff. Different ligand concentration ranges were chosen, as
compounds with a long residence time equilibrate more slowly, so a higher relative
concentration is required to ensure the experiments reach equilibrium within a
reasonable time frame (120 min), while still maintaining a good signal to noise.
Signal detection and data analysis. Signal detection was performed on a
Pherastar FS (BMG Labtech, Offenburg, Germany) using standard HTRF settings.
The terbium donor was always excited with three laser ﬂashes at a wavelength of
337 nm. A kinetic TR-FRET signal was collected at 20 s intervals both at 665 and
620 nm, when using red acceptor. HTRF ratios were obtained by dividing the
acceptor signal (665 nm) by the donor signal (620 nm) and multiplying this value
by 10,000. Probe dissociation rates were analyzed by displacement of the tracer
with a large excess of an unlabeled ligand known to bind to the same site with
similar or higher afﬁnity.
All experiments were analyzed by non-regression using Prism 6.0 (GraphPad
Software, San Diego, USA). Competition displacement binding data were ﬁtted to
sigmoidal (variable slope) curves using a “four parameter logistic equation”:
Y ¼ Bottomþ Top Bottomð Þ= 1þ 10 log EC50Xð ÞHillcoefficient
 
: ð1Þ
IC50 values obtained from the inhibition curves were converted to Ki values using
the method of Cheng and Prusoff48. PPHT-red association data were ﬁtted as
follows to a global ﬁtting model using GraphPad Prism 6.0 to simultaneously
calculate kon and koff using the following equation, where kob equals the observed
rate of association:
kob ¼ PPHT red½   kon þ koff : ð2Þ
Association and dissociation rates for unlabeled antagonists were calculated
using the equations described by Motulsky and Mahan26:
KA ¼ k1 L½  þ k2
KB ¼ k3 I½  þ k4
S ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
KA  KBð Þ2þ4k1 k3 LI10
18 r
KF ¼ 0:5  KA þ KB þ Sð Þ
KS ¼ 0:5  KA þ KB  Sð Þ
DIFF ¼ KF  KS
Q ¼ Bmax K1 L109DIFF
Y ¼ Q  k4 DIFFKF KS þ k4KFKF  exp KF Xð Þ 
k4KS
KS
 exp KS Xð Þ
 
ð3Þ
Where: X= Time (min), Y= Speciﬁc binding (HTRF ratio 665 nm/620
nm×10,000), k1= kon PPHT-red, k2= koff PPHT-red, L=Concentration of PPHT-
red used (nM), Bmax= Total binding (HTRF ratio 665 nm/620 nm×10,000),
I= Concentration of unlabeled antagonist (nM). Fixing the above parameters
allowed the following to be calculated: k3=Association rate of unlabeled ligand
(M−1 min−1), k4=Dissociation rate of unlabeled ligand (min−1). Dissociation of
PPHT-red was ﬁtted to a one phase mono-exponential decay function to estimate
the dissociation rate of PPHT-red directly. Speciﬁc binding was determined by
subtracting the nonspeciﬁc HTRF ratio from the total HTRF ratio.
Modeling rebinding. Rebinding describes the ability of a drug molecule to bind to
multiple receptors within a compartment before diffusing away into bulk, the
overall effect being extended target–receptor occupancy24. To examine this, we
utilized a model of an immunological synapse with a compartment volume of
0.176 μm3, which is within the range described for the dopamine synapse49. In this
model, the overall macroscopic reversal rate (kr) is described by the following
equation:
kr ¼ koff= 1þ kon  R=kð Þ; ð4Þ
where koff= dissociation rate from the receptor, kon= association rate onto the
receptor, R= surface receptor density ﬁxed at 1 × 1011 cm−2, and k-= the
diffusion rate out of the synaptic compartment into bulk aqueous, ﬁxed at
1.2 × 10−5 cm s−1. All data were analyzed using GraphPad Prism 6.0.
Comparing binding kinetics and clinical side effect proﬁle. To explore the role
of kinetics in determining on-target side effect liability, we correlated the kinetic
values determined in this study with published clinical data taken from a
comprehensive meta-analysis of clinically used APDs performed by Leucht and
colleagues31. The majority of studies covered in the Leucht et al. meta-analysis
included as subjects chronically ill patients with a history of APD exposure and the
potential for modiﬁed D2R availability. To address this, we repeated the above
analysis with reported data from available multiple-treatments studies in early
psychosis patients who entered studies with minimal exposure to APDs50–57. Odds
ratios for APD-induced EPS relative to spontaneous EPS in untreated patients
were calculated as follows: % APD-treated with EPS × % untreated without EPS/%
APD-treated without EPS × % untreated with spontaneous EPS. Unless otherwise
stated, correlation analyses were performed using a two-tailed Spearman rank
correlation allowing the calculation of the correlation coefﬁcient, rs. Although this
analysis does not assume a linear relationship, a simple trend line has been
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added to illustrate the positive or negative association between the two variables.
Differences were considered signiﬁcant at P< 0.05. All analysis were performed
using GraphPad Prism 6.0.
Data availability. The data that support the ﬁndings of this study are available
from the corresponding author on reasonable request.
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